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Abstract
Several studies have suggested the involvement of biogenic
monoaminergic neurotransmission in bipolar disorder and in
the therapy for this disease. In this study, the effects of the
mood-stabilizing drugs lithium, carbamazepine or valproate on
the dopaminergic and adrenergic systems, particularly on
D2-like and b-adrenergic receptors, were studied both in cul-
tured rat cortical neurones and in rat prefrontal cortex. In vitro
and in vivo data showed that stimulation of b-adrenergic
receptors with isoproterenol increased cyclic adenosine
monophosphate (cAMP) levels and this effect was signifi-
cantly inhibited by lithium, carbamazepine or valproate. The
activation of dopamine D2-like receptors with quinpirole de-
creased the isoproterenol-induced rise in cAMP in control
conditions. This inhibition was observed in vivo after chronic
treatment of the rats with carbamazepine or valproate, but not
after treatment with lithium or in cultured rat cortical neurones
after 48 h exposure to the three mood stabilizers. Dopamine
D2 and b1-adrenergic receptors were found to be co-localized
in prefrontal cortical cells, as determined by immunohisto-
chemistry, but western blot experiments revealed that recep-
tor levels were differentially affected by treatment with the
three mood stabilizers. These data show that mood stabilizers
affect D2 receptor-mediated regulation of b-adrenergic sig-
nalling and that each drug acts by a unique mechanism.
Keywords: adenylate cyclase, b-adrenergic receptors, bio-
genic monoamines, bipolar disorder, cyclic adenosine mono-
phosphate, dopamine D2 receptors.
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Bipolar disorder is a common psychiatric condition affecting
1% of the world population (Goodwin and Jamison 1990).
The most widely prescribed drugs for bipolar disorder are
commonly referred to as mood stabilizers, and include
lithium, valproate and carbamazepine. Although lithium is
the prototypical medication for the treatment of bipolar
disorder, there is a substantial group of patients (20–40%)
who do not respond to this treatment (Gershon and Soares
1997; Maj 2000). The anti-convulsants carbamazepine and
valproate, originally used to treat epileptic seizures, are an
alternative or adjunctive to lithium in bipolar disorder
treatment (Bowden 1996; Dunn et al. 1998; Post et al.
1998). Despite the widespread clinical use of lithium,
valproate and carbamazepine, the molecular mechanism(s)
underlying the mood-stabilizing effects are poorly under-
stood (Jope 1999; Manji and Lenox 2000).
Changes of noradrenergic and dopaminergic signalling
have been implicated in the pathogenesis and pharmacother-
apy of bipolar disorder and related diseases like depression
and schizophrenia (Avissar et al. 1996; Sundram et al. 2003;
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Wang and Goldman-Rakic 2004). Several lines of evidence
indicate that bipolar disorder is associated with a dopamin-
ergic dysregulation. Supporting this hypothesis, drugs that
inhibit dopaminergic transmission exert an anti-manic action
in bipolar disorder, whereas drugs that stimulate dopamine
synthesis, activate dopamine receptors or inhibit dopamine
re-uptake, often precipitate mania (Yatham 2002; Schatzberg
2004; Silverstone and Silverstone 2004). Interestingly,
whereas conventional neuroleptics and novel anti-psychotics,
which are also effective in treating acute mania (McElroy and
Keck 2000), act by directly inhibiting dopamine D2-like
receptors (Seeman and Lee 1975; Creese et al. 1976), the
mood-stabilizing drugs lithium, carbamazepine and valproate
do not directly block dopamine D2-like receptors and may
therefore act by a different mechanism, such as by dampen-
ing the downstream second messenger signalling pathways
activated by D2-like receptors (Yatham et al. 2002). On the
other hand, good evidence suggests that noradrenaline levels
are higher than normal in the body fluids of patients with
mania, and drugs such as lithium can blunt noradrenaline
signalling through the b-adrenoreceptors. Moreover, noradr-
energic drugs, such as tricyclic antidepressants, are partic-
ularly likely to promote manic switches and rapid cycling in
bipolar patients (Young 2001). A b-adrenergic hyperfunction
has been proposed to underlie manic episodes (Schreiber
et al. 1991), whereas bipolar depressed patients showed a
hypofuncfion of b-adrenergic receptors (Avissar et al. 1996).
Dopamine D2-like and b-adrenergic receptors belong to
the superfamily of GTP-binding protein (G-protein)-coupled
receptors that transduce extracellular stimuli to intracellular
signalling events. Agonist activation of the Gas-coupled
b-adrenergic receptor stimulates cyclic adenosine mono-
phosphate (cAMP) production, whereas acute activation of
the Gai/o-coupled D2-like dopamine receptors inhibits cAMP
accumulation to provide antagonistic control on receptor-
mediated adenylate cyclase (AC) activity at the cellular level
(Watts 2002). Bipolar disorder is associated with an
enhanced signalling activity of the cAMP cascade, as shown
by higher levels of Gas protein, stimulation of AC and
increased activity of the cAMP-dependent protein kinases
(PKA) (Young et al. 1993; Friedman and Wang 1996; Chang
et al. 2003). Most of the components of the cAMP signalling
pathways have been implicated in the actions of mood-
stabilizing agents (Jope 1999; Manji et al. 1995; Mørk and
Geisler 1995; Montezinho et al. 2004).
The aim of this study was to identify the mechanisms by
which the mood stabilizers lithium, valproate and carb-
amazepine affect the interaction of dopamine D2-like and
b-adrenergic signalling, both in vitro and in vivo. The effects
of the mood stabilizers on dopamine D2 and b1-adrenergic
protein levels were studied by immunoblotting of both
cultured cortical neurones and rat prefrontal cortex. The
cAMP levels produced by the isoproterenol-sensitive AC,
mimicking b-adrenergic activity, as well as the ability of D2
receptor stimulation to block the increase of isoproterenol-
stimulated cAMP levels, were measured in vitro in cultured
cortical neurones and in vivo by microdialysis in the rat
prefrontal cortex after treatment with mood-stabilizing drugs.
Materials and methods
Materials
The cAMP radioimmunoassay kits, [8-3H] and [125I], the polyviny-
lidene difluoride (PVDF) membrane, the alkaline phosphatase-
linked anti-mouse and anti-rabbit secondary antibodies, the
enhanced chemifluorescence (ECF) reagent and the low-fat milk
were obtained from Amersham Biosciences (Little Chalfont, UK).
Other reagents used in immunoblotting experiments were purchased
from Bio-Rad (Hercules, CA, USA). Neurobasal medium, B27
supplement and trypsin (USP grade) were purchased from Gibco
Invitrogen (Glasgow, UK). The 4-(3-butoxy-4-methoxybenzyl)-
2-imidazolidinone, 3-isobutyl-1-methylxanthine and the bicinchon-
inic acid reagent were obtained from Biomol (Plymouth Meeting,
PA, USA), Aldrich-Chemie (Steinheim, Germany) and Pierce
(Rockford, IL, USA.), respectively. Primary mouse monoclonal
and rabbit polyclonal antibodies against the dopamine D2 receptors
(sc-5303) and the b1-adrenoreceptor (sc-568), respectively, were
purchased from Santa Cruz Biotechnology Inc. (Santa Cruz, CA,
USA). Cy3-conjugated anti-rabbit and cy2-conjugated anti-mouse
antibodies were from Jackson Immuno Laboratories (West Grove,
PA, USA). Guide cannulas and microdialysis probes were from
CMA/Microdialysis AB (Stockholm, Sweden). All other reagents
were from Sigma Chemical Company (Madrid, Spain) or from
Merck (Darmstadt, Germany).
Preparation of rat prefrontal cortical neuronal cultures
Primary rat cortical neurones were prepared as previously
described (Montezinho et al. 2004). Cortical neurones were
cultured in Neurobasal medium supplemented with 2 mM L-gluta-
mine, 2% B27 supplement, penicillin (100 U/mL) and streptomy-
cin (100 lg/mL). The cells were plated on poly D-lysine (0.1 mg/
mL)-coated multiwell plates, at a density of 0.15 · 106 cells/cm2,
and the cultures were maintained at 37C in a humidified
atmosphere of 5% CO2/95% air.
Experimental treatments on cultured cortical neurones
After 5 days in culture, cortical neurones were pre-exposed to
therapeutic relevant doses of LiCl (1 mM), valproate (0.05 mM) or
carbamazepine (0.5 mM), for 2 days. Non-exposed cultures served
as a control. After this time period, neurones were pre-incubated
with the cAMP phosphodiesterase inhibitor, 4-(3-butoxy-4-meth-
oxybenzyl)-2-imidazolidinone (Ro-201724) 25 lM, 15 min (Reeves
et al. 1987) and then treated or not (basal cAMP levels) with
isoproterenol (10 lM; 15 min), or isoproterenol (10 lM; 15 min)
after pre-treatment with quinpirole (10 lM, 5 min). The medium
was then removed and the cells were scraped off the plates in 1 mL
50 mM Tris/4 mM EDTA buffer, pH 7.35, after washing with an ice-
cold phosphate-buffered saline (PBS) solution. The extracts were
boiled at 90C for 4 min, then centrifuged at 14 000 g for 5 min at
4C. Supernatant fluids were used to quantify cAMP levels. Levels
of cAMP were normalized to the protein concentration using the
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bicinchoninic acid assay and expressed as a percentage relative to
the control cAMP levels. For western blot analysis of receptor
expression, cortical neurones exposed to different treatments for
48 h were washed twice with PBS and then lysed at 4C with lysis
buffer [in mM: 50 KCl, 50 Piperazine-1,4-bis(2-ethanesulfonic
acid; PIPES), 10 EGTA, 2 MgCl2, pH 7.4] supplemented with
0.2% Triton X-100, 100 lM phenylmethanesulfonyl fluoride, 1 mM
dithiothreitol, 1 mg/mL chymostatin, 1 mg/mL leupeptin, 1 mg/mL
antipain and 5 mg/mL pepstatin. The lysates were collected in
microcentrifuge tubes, sonicated for 10 s, and centrifuged at
14 000 g for 10 min. Pellets were resuspended in 5% sodium
dodecyl sulfate (SDS) and stored at – 80C for further use. Protein
content was determined by the bicinchoninic acid assay, using
bovine serum albumin (BSA) as standard.
Animals and drug treatments
Male Wistar rats, initially weighing 200–250 g, housed two per cage
under a 12 h light/dark cycle were used (lights on at 06.00 hours).
Food and water were available ad libitum. The lithium-treated group
received 50 mM LiCl/kg diet for 3 weeks with free access to NaCl
during the treatment period. The rats fed with the lithium-
supplemented diet achieved a plasma lithium level (determined by
flame photometry) of 0.84 ± 0.11 mM. The carbamazepine-treated
rats were fed with 5 g carbamazepine/kg diet, whereas the
intraperitoneal dosage of valproate was 250 mg/kg once daily for
3 weeks. The doses of carbamazepine and valproate used were
previously shown to produce the therapeutic drug levels found in the
plasma (Mørk and Jensen 2000). Control rats received standard diet,
and vehicle-treated rats received intraperitoneal injections with
sterile-filtered saline solution (NaCl 0.9%) once daily for 3 weeks.
Ethical permissions for the studies were granted by the animal
welfare committee appointed by the Danish Ministry of Justice, and
all animal procedures were carried out in compliance with the EC
directive 86/609/EEC and with the Danish law regulating experi-
ments on animals.
Surgery for microdialysis
Two days before completing the treatment, rats were anaesthetized
with 2 mL/kg Hypnorm/Dormicum (fentanyl citrate, 0.079 mg/mL;
fluanisone, 2.5 mg/mL; midazolam, 1.25 mg/mL) and intracerebral
guide cannulas (CMA/12) were stereotaxically implanted into the
brain, positioning the dialysis probe tip in the prefrontal cortex (co-
ordinates: 3.2 mm anterior to bregma; lateral, ) 0.8 mm; 3.3 mm
ventral to duramater) (Paxinos and Watson 1986). Anchor screws
and acrylic cement were used for fixation of the guide cannulas. The
body temperature of the animals was monitored by a rectal probe
and maintained at 37C. The rats were allowed to recover from
surgery for 2 days, housed individually in cages.
Microdialysis procedure
On the day of the experiment, a microdialysis probe (CMA/12,
0.5 mm diameter, 2 mm length) was inserted through the guide
cannula. The probes were connected via dual channel swivel to a
microinjection pump. Perfusion of the microdialysis probe with
filtered Ringer’s solution [in mM: 145 NaCl, 3 KCI, 1 MgCl2.6H2O,
1.2 CaCl2.2H2O, 0.25 3-isobutyl-1-methylxanthine (IBMX),
pH 7.4] was initiated shortly before insertion of the probe into the
brain and continued for the duration of the experiment, at a constant
flow of 1.36 lL/min. After 180 min of stabilization, the experiments
were initiated. A 30 min sampling regime was used throughout the
experimental period. Time points were corrected for lag time of the
perfusate from the microdialysis site to the probe outlet. Basal
cAMP levels were taken as the average cAMP concentration in four
consecutive samples. Thereafter, the agent of interest (100 lM
quinpirole, or 2.5 mM isoproterenol, or 100 lM quinpirole simulta-
neously with 2.5 mM isoproterenol) dissolved in Ringer’s solution
was infused through the probe for 30 min and seven further samples
were collected. The dialysates were stored at – 80C until cAMP
determination.
Tissue preparation for immunoblotting
The rats were killed by decapitation and the brains rapidly
removed. The cerebral prefrontal cortices were dissected at 4C
and homogenized in 5 volumes of 10 mM Tris (pH 7.2), 1 : 100
protease inhibitor cocktail, 0.1 mM phenylmethysulfonyl fluoride
and 1% orthonovanadate. Nonidet P-40 (1%) was added for
30 min and then homogenates were centrifuged at 18 000 g, 4C,
for 20 min. Supernatant fluids (cytoplasmic fraction) were
collected and stored at ) 80C until further use. SDS (1%) was
added to the pellet for 30 min and this was further centrifuged
at 18 000 g, 4C, for 20 min. Supernatant fluids (membrane
fraction) were collected and stored at – 80C for further use.
Protein content was determined by the bicinchoninic acid assay
with BSA as standard.
Quantification of cAMP levels
The content of cAMP in cortical lysates and microdialysis dialysates
was determined in duplicate using the [8-3H] and [125I] radio-
immunoassay kits, respectively, following the manufacturer’s
instructions. In the microdialysis dialysates, the high-sensitivity
method following acetylation of the samples was used. The lower
limit of detection for cAMP was 2 fmol per tube and basal levels
were at least four times the detection limit.
Immunohistochemistry
Male Wistar rats were anaesthetized with 680 mg/kg avertin
intraperitoneally and perfused transcardially with PBS followed
by phosphate-buffered 4% paraformaldehyde, for 10 min. The
brains were removed, post-fixed overnight in the same fixative
and then embedded in paraffin. Prefrontal cortex sections of 4 lm
were picked up on gelatin-coated glass slides. Following xylene
deparaffination and alcohol rehydration, the slides were heated in
a microwave oven for antigen retrieval (Cattoretti et al. 1993; Shi
et al. 1995) at 700 W for 10 min (2 · 5 min) in 0.01 citrate
buffer, pH 6.0. Sections were blocked for 20 min with 5% normal
swine serum in PBS supplemented with 1% BSA and 0.3%
Triton X-100, and then incubated overnight at 4C with the
specific primary antibodies mouse anti-dopamine D2 receptor
and rabbit anti-b1-adrenoreceptor diluted 1 : 100 and 1 : 500,
respectively. These antibodies were previously used in immuno-
histochemistry (anti-dopamine D2; Zou et al. 2005) and immuno-
blotting (anti-b1; Dincer et al. 2001). Sections were thoroughly
washed in PBS with 0.25% BSA and 0.1% Triton X-100. Then,
secondary cy3-conjugated anti-rabbit and cy2-conjugated anti-
mouse antibodies were applied to sections after dilution of
1 : 250 and 1 : 100 in PBS, respectively, and incubated for
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60 min at 22–25C. Slides were washed with PBS and then
coverslipped with Dako (Carpinteria, CA, USA) fluorescent
mounting medium. As negative controls, adjacent sections were
incubated without primary antibody. Brain sections were analysed
using the Zeiss upright fluorescence microscope equipped with
the LSM 510 Meta confocal system (Carl Zeiss AG, Go¨ttingen,
Germany).
Western blot
For western blot analysis, 60 lg of each protein sample were
used, after addition of a sixfold concentrated sample buffer (0.5 M
Tris, 30% glycerol, 10% SDS, 0.6 M dithiothreitol, 0.012%
bromophenol blue) and boiling for 5 min at 95C. Proteins were
separated by electrophoresis on 7.5% acrylamide/bisacrylamide
gels and transferred electrophoretically to polyvinylidene difluo-
ride (PVDF) membranes which were subsequently blocked for
1 h at 22–25C in Tris-buffered saline (in mM: 137 NaCl and 20
Tris-HCl, pH 7.5) containing 0.1% Tween 20 (TBS-T) and 5%
low-fat milk. Incubation with the primary antibodies (mouse anti-
dopamine D2 receptor, diluted 1 : 100, or rabbit anti-b1-adrener-
gic receptor, diluted 1 : 1000, in TBS-T with 1% low-fat milk)
was performed overnight at 4C. After extensive washing in
TBS-T with 0.5% low-fat milk, the membranes were incubated
for 1 h at room temperature (22–25C) with alkaline phosphatase-
or horseradish peroxidase (HRP)-linked secondary antibodies
(anti-mouse IgG diluted 1 : 5000 and anti-rabbit IgG diluted
1 : 10 000 in TBS-T with 1% low-fat milk). Protein immunore-
activity was visualized by chemiluminescence on a Fuji Imager
4400 chemiluminescence detection unit (Fujifilm Danmark A/S,
Vedbaek, Denmark) or by chemifluorescence on a Storm 860 Gel
and Blot Imaging System (Amersham Biosciences).
Statistical analysis
The levels of cAMP in the dialysates were calculated as
fmol/20 lL dialysate. The average of the four basal values prior
to isoproterenol and quinpirole plus isopreoterenol infusions was
taken as baseline and set to 100%. The changes in cAMP levels
occurred mostly during the first two samples collected after the
beginning of isoproterenol and quinpirole plus isopreoterenol
infusions. Therefore, the maximal release of cAMP, measured
after 30 min post-infusion with different treatments, was deter-
mined and differences were analysed using one-way ANOVA,
followed by the Bonferroni test for multiple comparisons, as
indicated in the figure captions. However, since in some cases the
extracellular accumulation of cAMP was slower, the total amount
of cAMP produced during 150 min post-infusion (area under the
curves) was also calculated, and the results were expressed as a
percentage of the total amount of cAMP produced during
150 min post-infusion with isoproterenol in control or vehicle-
treated rats. Differences were analysed using one-way ANOVA,
followed by the Bonferroni test for multiple comparisons, as
indicated in the figure captions. The density of the bands in the
western blots was quantified using QUANTITY ONE 1D-ANALYSIS
Software, then data were expressed as percentage of control or
vehicle, and analysed using one-way ANOVA, followed by the
Bonferroni test for multiple comparisons, as indicated in the
figure captions. The data obtained were expressed as means ±
SEM values and p < 0.05 was considered significant.
Results
Determination of intracellular cAMP levels in
cerebrocortical neurones
Figure 1 shows the cAMP accumulation in cultured cortical
cells pre-exposed or not (control) to lithium (1 mM),
carbamazepine (0.05 mM) or valproate (0.5 mM), during
Fig. 1 Effects of lithium, valproate and carbamazepine on the intra-
cellular cAMP levels in cortical neurones under basal conditions and
after stimulation with isoproterenol or quinpirole plus isoproterenol.
Neurones were pre-exposed or not (control) to 1 mM lithium, 0.05 mM
carbamazepine or 0.5 mM valproate, for 48 h. After this period, neu-
rones were incubated with Ro-201724 (25 lM, 15 min) and were then
treated or not (basal) with isoproterenol (10 lM; 15 min), or with iso-
proterenol together with quinpirole (10 lM; 15 min). In the latter
experimental conditions, the cells were pre-treated with 10 lM quin-
pirole for 5 min. The cAMP levels were measured as described in the
Methods section. The average value of basal cAMP level for all cells
tested (101.4 ± 21.0 nmol/lg protein) was set to 100%. Data are
means ± SEM, for the indicated number of independent experiments,
performed in duplicate. Data were analysed by one-way ANOVA, fol-
lowed by posthoc Bonferroni’s test for multiple comparisons.
###p < 0.001, #p < 0.05, compared with control isoproterenol-treated
cells; +p < 0.05, ++p < 0.01, compared with control quinpirole plus
isoproterenol-stimulated cells; &&&p < 0.001, compared with control of
untreated cells; *p < 0.05, **p < 0.01, compared with neurones pre-
exposed to LiCl and valproate, respectively.
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48 h. After pre-treatment with the mood-stabilizing agents,
cells were exposed to isoproterenol (10 lM), for 15 min, in
the absence or presence of quinpirole (10 lM), and then
intracellular cAMP levels were determined. The average
value of basal cAMP level for all cells tested
(101.4 ± 21.0 nmol/lg protein) was set to 100%. Isopro-
terenol-stimulated cAMP production was twofold above
basal levels (264.6 ± 14.3%, p < 0.001). Lithium, carbama-
zepine or valproate had no effect on the basal cAMP
production, but partially inhibited isoproterenol-induced
cAMP accumulation (lithium: 160.7 ± 25.6%, p < 0.001;
carbamazepine: 143.9 ± 13.1%, p < 0.001; valproate:
195.4 ± 21.8%, p < 0.05). The agonist of dopamine D2-like
receptors, quinpirole, had no effect on the basal cAMP
accumulation (data not shown) but inhibited isoproterenol-
enhanced cAMP levels in untreated neurones (158.4 ±
16.8%, p < 0.001). In neurones pre-exposed to lithium,
carbamazepine or valproate, the ability of quinpirole to
reduce the isoproterenol-evoked rise in cAMP was
decreased (lithium: 249.1 ± 28.4%, p < 0.05; valproate:
259.0 ± 18.4%, p < 0.01; carbamazepine: 243.8 ± 21.5%,
p < 0.05).
Regulation of cAMP levels in prefrontal cortex
In order to confirm the data obtained with cultured cortical
neurones, parallel in vivo experiments were performed on
prefrontal cortex of freely-moving rats using microdialysis.
Extracellular concentration of cAMP can be monitored in
the prefrontal cortex of freely-moving animals by micro-
dialysis (Masana et al. 1991, 1992). It has been demon-
strated that a fraction of intracellular cAMP generated by
activation of AC is extruded into the extracellular fluid in
proportion to its accumulation in cells. Therefore, the efflux
of cAMP can be used to study the cAMP second messenger
system in intact brains, using in vivo microdialysis (Mørk
and Geisler 1994).
Preliminary experiments showed that extracellular levels
of cAMP declined to stable values within 180 min (data not
shown). Therefore, the experiments were started 180 min
after the insertion of the probes and the baseline values were
stable throughout the experiment (Fig. 2). The average basal
cAMP levels for all animals tested was 9.68 ± 2.10 fmol/
20 lL. Average basal levels were not different in valproate-
treated rats but were significantly increased in lithium-treated
rats, to 13.17 ± 1.21 fmol/20 lL (p < 0.05), and decreased
in carbamazepine-treated rats, to 7.82 ± 0.34 fmol/20 lL
(p < 0.01) (Fig. 2).
The effect was then determined of local infusion of
isoproterenol, or quinpirole together with isoproterenol, on
the extracellular cAMP levels in control or vehicle-treated
rats, and in lithium-, carbamazepine- or valproate-treated
rats. In a preliminary series of experiments, it was confirmed
that infusion of isoproterenol in the rat prefrontal cortex
(500 lM, 1 mM, 2.5 mM, 5 mM and 10 mM) increased cAMP
production in a concentration-dependent manner, and this
effect was inhibited by quinpirole (50 lM, 100 lM, 500 lM,
1 mM and 2.5 mM) (data not shown). Accordingly, the
concentrations of isoproterenol and quinpirole used in all
subsequent experiments were 2.5 mM and 100 lM, respect-
ively, which were found to be the minimal concentrations
that produced an observable effect under our experimental
conditions (data not shown). These concentrations of
isoproterenol and quinpirole cannot be directly compared
with those used in in vitro experiments and with extra-
cellular levels obtained in the brain (5–15% of the
initial concentrations), since the extracellular concentra-
tion achieved in brain tissue under the present conditions
depends on diffusion across the dialysis membrane (Mørk
and Geisler 1994).
The infusion of isoproterenol in the prefrontal cortex of
control and vehicle-treated rats for 30 min increased
cAMP levels to approximately 234.6 ± 12.2% (Fig. 3a)
Fig. 2 Effect of chronic treatment, with doses yielding therapeutic
plasma levels of lithium, carbamazepine and valproate, on basal
cAMP levels in the prefrontal cortex of freely-moving rats. Extracellular
cAMP levels in the dialysates were measured by radioimmunoassay
analysis. The rats were treated for 3 weeks with doses yielding
therapeutic plasma levels of lithium (n ¼ 6) or carbamazepine (n ¼ 6)
in the diet, whereas others were treated with doses yielding thera-
peutic plasma levels of valproate (n ¼ 6) by intraperitoneal injections,
once daily, for 3 weeks. Control rats (n ¼ 6) received standard diet,
whereas vehicle-treated rats (n ¼ 4) received intraperitoneal injec-
tions with saline solution, once daily, for 3 weeks.
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and 272.1 ± 12.0% (Fig. 3d) of the basal values, and the
extracellular amount of cAMP returned to basal values by
150 min post-infusion. In lithium-, carbamazepine- or
valproate-treated rats there was a significant decrease in the
isoproterenol-stimulated cAMP levels determined after
30 min of infusion (lithium: 131.9 ± 5.8%, p < 0.01;
carbamazepine: 159.0 ± 8.5%, p < 0.01; valproate:
137.9 ± 8.7%, p < 0.01) (Figs 3b, c and e), as well as
a decrease in the total evoked increase in extracellular
cAMP (lithium: 85.1 ± 3.7%, p < 0.01; carbamazepine:
87.5 ± 1.6%, p < 0.05; valproate: 69.5 ± 2.4%, p < 0.001),
when compared with the effect observed in control or
vehicle-treated rats (Fig. 3f). Local infusion of the D2-like
receptor agonist, quinpirole, significantly inhibited the effect
of isoproterenol on the extracellular cAMP, measured 30 min
after the infusion of the agonist (control rats: 132.5 ±
5.8%, p < 0.01; vehicle-treated rats: 141.0 ± 9.1, p < 0.01)
(Figs 3a and d). The total increase in extracellular cAMP
evoked by isoproterenol within 150 min was also signifi-
cantly decreased in the presence of quinpirole (control rats:
77.0 ± 1.6%, p < 0.001; vehicle-treated rats: 74.9 ± 2.7,
p < 0.001) (Fig. 3f). As observed in cultured cortical neu-
rones, in lithium-treated rats the activation of D2-like
receptors did not inhibit the isoproterenol-induced increase
in extracellular cAMP. Instead, there was an increase in
extracellular cAMP measured 30 min after the infusion
(188.2 ± 19.1%, p < 0.01) (Fig. 3b) when compared with
the amount of the cyclic nucleotide determined in control rats
under the same conditions (132.5 ± 5.8%) (Fig. 3a) or in
animals treated with lithium and infused only with isopro-
terenol (131.9 ± 5.8%) (Fig. 3b). Treatment with lithium
also increased the total extracellular accumulation of cAMP
induced by quinpirole and isoproterenol, and produced
within 150 min (77.0 ± 1.6 vs. 94.7 ± 4.4%, p < 0.01)
(Fig. 3f). In contrast to what was observed with cultured
cortical neurones and lithium-treated rats, in carbamazepine-
or valproate-treated rats, quinpirole infusion did not
significantly change the isoproterenol-induced increase in
extracellular cAMP produced 30 min post-infusion (Figs 3c
and e) (176.9 ± 8.3% and 158.0 ± 11.7%, respectively),
when compared with the effect observed in control and
vehicle-treated rats under the same conditions (132.5 ± 5.8%
and 137.9 ± 8.7%, respectively) (Figs 3a and d), or in
animals treated with carbamazepine or valproate and infused
only with isoproterenol (159.0 ± 8.5% and 137.9 ± 8.7%,
respectively) (Figs 3c and e). Treatment with carbamazepine
or valproate did not significantly change the total evoked
extracellular accumulation of cAMP measured during
150 min following infusion with quinpirole and isoprotere-
nol (84.7 ± 3.5% and 85.9 ± 2.2%, respectively), when
compared with the values obtained in control and vehicle-
treated rats, 77.0 ± 1.6% and 74.9 ± 2.7%, respectively
(Fig. 3f). In carbamazepine-treated rats, the activation of
D2-like receptors did not significantly interfere with the total
isoproterenol-induced increases in extracellular cAMP,
although the effect occurred at a slower rate.
The activation of D2-like receptors had no effect on basal
cAMP levels under control conditions (control rats:
100.4 ± 18.4%; vehicle-treated rats: 104.0 ± 11.3%). How-
ever, in lithium-treated rats, the activation of dopamine D2-
like receptors, with quinpirole, significantly increased cAMP
levels to 155.1 ± 9.3%, p < 0.05. In contrast, in carbamaze-
pine- and valproate-treated rats, the infusion of quinpirole did
not significantly change basal cAMP levels (114.4 ± 8.9%
and 98.7 ± 13.6%, respectively, vs. 100.4 ± 18.4% and
104.0 ± 11.3%) (Fig. 4).
Immunohistochemistry
The dopamine D2 receptor is the predominant member of
the family of D2-like dopamine receptors in the brain
(Emilien et al. 1999) and the b1-adrenergic receptors are
the most abundant members of b-adrenergic receptors in
the cerebral cortex (Rainbow et al. 1984). To confirm that
dopamine D2 and b1-adrenergic receptors are co-localized
in cells of the prefrontal cortex, allowing the interactions
at the second messenger level, immunohistochemistry
studies were performed. Double-labelling experiments
confirmed the co-existence of dopamine D2 and b1-
adrenergic receptors in the majority of the cells (Fig. 5).
The prefrontal cortex of sections prepared after treating
rats for 3 weeks with lithium, carbamazepine or valproate
suggested a loss of dopamine D2 receptors. In contrast, in
valproate-, carbamazepine- and lithium-treated rats the
b1-adrenergic receptors seemed to be down-regulated, up-
regulated or not changed, respectively (Fig. 5). Immuno-
histochemical controls were prepared by omitting addition
of the primary antibody in some slices, and it was
observed that no significant amount of secondary binding
occurred.
Immunoblotting
In order to confirm the immunostaining data, the dopamine
D2 and b1-adrenergic receptor protein levels were determined
in membranes prepared from cultured rat cortical neurones
and from rat prefrontal cortex, pre-treated or not with the
mood-stabilizing agents, by western blot analysis, using the
same anti-D2 and anti-b1 specific antibodies used for
immunohistochemistry. A strong immunoreactivity was
observed at approximately 50 kDa and 64 kDa, which are
the predicted molecular weights for the dopamine D2 and
b1-adrenergic receptor proteins, respectively (Fig. 6a). The
two bands obtained with the dopamine D2 antibody could be
due to the two isoforms of the receptor, D2 long (D2L) and
short (D2S), which are encoded by splice variants of a single
gene and detected by this antibody. Densitometry analysis of
the bands at approximately 50 kDa showed that lithium,
valproate and carbamazepine treatments decreased the
immunoreactivity of the dopamine D2 receptor protein band,
Effects of mood stabilizers on D2 and b receptors 1341
 2006 The Authors
Journal Compilation  2006 International Society for Neurochemistry, J. Neurochem. (2006) 96, 1336–1348
by 87.6 ± 3.0% (p < 0.01), 90.5 ± 2.7% (p < 0.01) and
86.5 ± 3.1% (p < 0.01), respectively, in membranes from
cultured rat cortical neurones, when compared with the
control (103.9 ± 1.7%) (Fig. 6b). Similar results were
obtained in the prefrontal cortex tissue, where lithium,
valproate and carbamazepine reduced D2 protein levels by
69.6 ± 3.9% (p < 0.01), 97.9 ± 6.2% (p < 0.01) and
76.5 ± 5.0% (p < 0.05), respectively, when compared with
control (97.9 ± 4.7%) and vehicle-treated rats (101.9 ±
4.3%) (Fig. 6c). In cultured cerebrocortical neurones, only
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valproate had an effect on b1-adrenergic receptors by
decreasing the amount of the receptor present (101.9 ±
4.3%, p < 0.05), compared with control (105.6 ± 6.7%)
(Fig. 6b, graph). In contrast, in vivo treatment of rats with
carbamazepine, valproate or lithium up-regulated (129.6 ±
7.0%, p < 0.01), down-regulated (70.8 ± 4.4%, p < 0.01)
or had no effect (100.4 ± 3.6%) on b1-adrenergic recep-
tor levels, respectively, when compared with control
(101.3 ± 1.6%) and vehicle-treated (100.9 ± 4.6%) rats
(Fig. 6c).
Discussion
The effects of mood-stabilizing drugs on the dopaminergic
and adrenergic systems were studied via analysis of the
intracellular cAMP accumulation induced by activation of
b-adrenergic and/or dopamine D2-like receptors. The change
in the levels of dopamine D2 and b1-adrenergic receptors
under the same experimental conditions was also investi-
gated. In the present study, we showed that there is a cross-
talk between dopamine D2-like and b-adrenergic receptor
activities in the rat brain cortical region, which is differen-
tially affected by therapeutic concentrations of the mood-
stabilizing drugs lithium, carbamazepine and valproate.
Indeed, in vivo and in vitro data showed that activation of
dopamine D2-like receptors inhibits b-adrenergic receptor-
stimulated cAMP production. In vitro this inhibition was
attenuated by lithium, carbamazepine and valproate, whereas
in vivo only lithium had such an effect. Consistent with this
regulatory role on AC activity, dopamine D2 and
b1-adrenergic receptors are co-localized in the rat prefrontal
cortex and their protein levels are changed by mood
stabilizers, as determined by immunohistochemistry and
immunoblotting, respectively.
In vivo chronic treatment with lithium increased the
intracellular cAMP content in the rat prefrontal cortex by
40%. This type of effect of lithium may be attributed to the
inhibition of Gi, which is the G-protein preferentially
activated under basal conditions (Masana et al. 1991, 1992;
Jope 1999; Montezinho et al. 2004). However, our results
showing a functional cross-talk between b-adrenergic and
Fig. 4 Infusion of quinpirole (100 lM) in the prefrontal cortex of freely-
moving rats (starting at arrow) on the extracellular cAMP levels in the
prefrontal cortex of control, vehicle-, lithium-, carbamazepine- or val-
proate-treated rats. Baseline levels of cAMP were taken as the aver-
age cAMP content in the four consecutive samples collected from 3 h
after the insertion of the probe. Thereafter, 100 lM of quinpirole, dis-
solved in Ringer’s solution, were infused through the probe for 30 min,
and six samples were collected post-infusion. Extracellular cAMP
levels in the dialysates were measured by radioimmunoassay analysis
and expressed as percentages of the baseline. Results are means ±
SEM, from four independent experiments. The rats were treated or not
with doses yielding therapeutic plasma levels of lithium, carbamaze-
pine or valproate, for 3 weeks, as indicated in the legend of Fig. 2.
Data were analysed by one-way ANOVA, followed by posthoc Bonfer-
roni’s test for multiple comparisons. *p < 0.05 compared with the
cAMP produced 30 min after the infusion of quinpirole in control rats.
Fig. 3 Effect of the local infusion of isoproterenol (2.5 mM) or quinpi-
role (100 lM) simultaneously with isoproterenol (2.5 mM) (starting at
arrow) on the maximal extracellular cAMP levels produced 30 min
post-infusions [(a) Control rats; (b) lithium-treated rats; (c) carb-
amazepine-treated rats; (d) vehicle-treated rats; (e) valproate-treated
rats] and on total cAMP levels (corresponding to the area under the
curves), measured within 150 min post-infusions (f). Basal cAMP level
was taken as the average cAMP concentration in the four consecutive
samples collected from 3 h after the insertion of the probe, prior to
isoproterenol (8.9 ± 2.6 fmol/20 lL, n ¼ 6) and quinpirole plus iso-
proterenol infusions (9.4 ± 1.1 fmol/20 lL, n ¼ 4). Thereafter, the
agent of interest (2.5 mM isoproterenol or 100 lM quinpirole plus
2.5 mM isoproterenol) dissolved in Ringer’s solution was infused
through the probe, for 30 min, and seven samples were then collected.
Extracellular cAMP levels in the dialysates were measured by radio-
immunoassay analysis and expressed as percentages of the basal
value (a–e), or expressed as a percentage of the percentage of the
total amount of cAMP produced during 150 min post-infusion with
isoproterenol in control or vehicle-treated rats (f). Results are means ±
SEM, from four to six independent experiments. The rats were treated
or not with doses yielding therapeutic plasma levels of lithium, carb-
amazepine or valproate, for 3 weeks, as indicated in the legend of
Fig. 2. Data were analysed by one-way ANOVA, followed by posthoc
Bonferroni’s test for multiple comparisons. ***p < 0.001, compared
with the cAMP produced 30 min after the infusion of isoproterenol in
control rats; +++p < 0.001, compared with the cAMP produced 30 min
after the infusion of isoproterenol in vehicle-treated rats; §§p < 0.01,
compared with the cAMP produced 30 min after the infusion of quin-
pirole plus isoproterenol in control rats; &&p < 0.001, compared with
the cAMP produced 30 min after the infusion of quinpirole plus iso-
proterenol in lithium-treated rats.
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dopamine D2-like receptors, and a selective down-regulation
of the dopamine D2 receptors by chronic treatment with
lithium, indicate that the loss of these receptors, which are
coupled to the inhibition of AC, may also account for the
increase in the basal cAMP levels. The decrease in dopamine
D2 receptor levels following lithium treatment might also
have contributed to the lack of effect of D2 receptor
stimulation on isoproterenol-evoked intracellular cAMP
accumulation in the in vitro and in vivo studies. Recent
evidence has implicated cortical D2 receptors as the import-
ant sites of action of anti-psychotics. Psychotic and manic
symptoms may result from the supersensitivity of a subset of
cortical pyramidal neurones to stimulation of D2 receptors
(Yatham et al. 2002; Schatzberg 2004; Silverstone and
Silverstone 2004). Therefore, part of the anti-manic action
of chronic lithium treatment could be mediated by a decrease
in D2 receptor levels shown in this study. In contrast to
lithium, in vivo chronic treatment with carbamazepine
inhibited basal cAMP levels by 20%. This is in agreement
with previous findings showing that carbamazepine decrea-
ses the basal concentrations of cAMP in mouse cerebral
cortex and cerebellum (Palmer et al. 1979), as well as in
rabbit CSF (Myllyla 1976). In contrast with the results
obtained with lithium, the in vivo effects of carbamazepine
on the intracellular cAMP content under resting conditions
do not correlate with the down-regulation of dopamine D2
receptors and the up-regulation of b-adrenergic receptors
under the same conditions. These changes in AC-coupled
receptor would be expected to increase the intracellular
cAMP content. This discrepancy may be explained by the
fact that the action of carbamazepine, at therapeutically
relevant concentrations, is independent of the phosphodiest-
(a) (b) (c)
Fig. 6 Changes in b1AR and DAD2R protein levels following lithium,
valproate or carbamazepine treatments. Representative western blots
showing b1AR and DAD2R, and actin immunoreactivity, in protein
extracts from cultured rat cortical neurones treated with lithium, val-
proate or carbamazepine for 48 h (a), or from the prefrontal cortex of
rats treated for 3 weeks with the same drugs (b). The bottom panels
represent normalized levels of b1AR and DAD2R immunoreactivity.
The results are presented as percentage of the controls/vehicles and
data are means ± SEM, from four to six independent experiments.
Data are means ± SEM and were analysed by one-way ANOVA, fol-
lowed by posthoc Bonferroni’s test for multiple comparisons.
*p < 0.05, **p < 0.001, compared with control rats; +p < 0.05,
++p < 0.001, compared with vehicle-treated rats; #p < 0.05,
##p < 0.001, compared with control neurones. Ctrl, control; Li+, lith-
ium; CBZ, carbamazepine; Veh, vehicle; VPA, valproate.
Fig. 5 Representative confocal images of double immunofluores-
cence b1 adrenergic receptors (b1AR) and dopamine D2 receptor
(DAD2R) in rat prefrontal cortical slices obtained from control rats or
rats treated for 3 weeks with doses yielding therapeutic plasma levels
of lithium, carbamazepine or valproate. b1AR immunoreactivity is
revealed by red cy3 fluorescence, whereas DAD2R-positive cells are
identified by green cy2 immunofluorescence in the same sections.
Scale bar, 10 lm.
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erase activity and is mediated by a Gi-independent mechan-
ism (Chen et al. 1996a). Thus, the inhibitory effect of
carbamazepine on cAMP levels may be exerted primarily at
the level of cAMP production, acting directly on AC and/or
through factor(s) that are tightly associated with this enzyme
(Chen et al. 1996a). A direct inhibitory action of carbamaze-
pine on AC could also explain our finding that in vivo
chronic carbamazepine treatment attenuated the isoprotere-
nol-evoked cAMP production, despite an increase in the b1-
receptor levels and the lack of a further effect of D2 receptor
activation. The changes in receptor levels could represent a
compensatory mechanism in the in vivo conditions, although
this was not observed in cultured cortical neurones. Recently,
it was proposed that the b-adrenoreceptors mediating cAMP
efflux after norepinephrine stimulation are localized predom-
inantly on glial cells in the rat brain cortex (Stone et al. 1990;
Stone and John 1991). This is not the case in the neuronal
cultures used in the present work, since they contain a very
small percentage of astrocytes (Brewer et al. 1993). Identi-
fication of the cells that contribute to the cAMP responses
observed both in vivo and in vitro, and the regulating
mechanisms involved, remain to be clarified. In addition,
Khan et al. found that approximately one-third of the total
D2 receptor binding sites in the cortex are associated with
astroglia (Khan et al. 2001). In vivo chronic administration
of valproate significantly reduced both the b1-adrenoreceptor
and dopamine D2 receptor immunoreactivity in the rat
prefrontal cortex. The down-regulation of both receptor types
did not affect the basal levels of cAMP, but the decrease in
the density of b-adrenoreceptors is likely to be reflected in
the decrease in isopreterenol-evoked, receptor-mediated
cAMP production. Furthermore, dopamine D2 receptor
stimulation did not further attenuate cAMP production,
which could be related to the lower levels of receptor protein
after chronic treatment with valproate. Supporting our
findings, previous studies showed that valproate selectively
down-regulates b1-adrenergic receptors in vitro, in rat C6
glioma cells (Chen et al. 1996b).
Each of the mood-stabilizing drugs modulated dopamine
D2 and b-adrenergic receptor-regulated cAMP levels by a
distinct mechanism in vivo. The effects of carbamazepine are
most likely due to direct inhibition of AC; lithium may act by
affecting dopamine D2 receptor-mediated signalling and
valproate, by down-regulating b-adrenergic transmission.
Interestingly, the results obtained in vitro with cultured
cerebrocortical neurones did not fully correlate with the
in vivo findings. In cultured cortical neurones, lithium,
valproate and carbamazepine did not significantly affect
basal cAMP levels. The increase in b-adrenergic receptor-
mediated production of cAMP was attenuated by all three
drugs both in vitro and in vivo. This attenuation was reversed
by dopamine D2-like receptor stimulation in controls and
after chronic treatment of the rats with carbamazepine or
valproate, but not after treatment with lithium or in cultured
cortical neurones after pre-exposure to the three mood-
stabilizing drugs. Therefore, we propose that in in vitro
conditions, the three mood-stabilizing drugs used interfere
with the ability of quinpirole to blunt isoproterenol effects,
which may result from the action of these drugs downstream
of second messenger signalling pathways activated by D2-
like receptors (Yatham et al. 2002). The overall results
obtained in the present work suggest that additional mech-
anisms are operative in vivo compared with in vitro. It can be
speculated that dopaminergic and noradrenergic neurotrans-
mitter levels released by afferent projections participate in the
regulation of these monoaminergic systems. In agreement
with this hypothesis, a decrease in the dopamine concentra-
tion in prefrontal cortex (Baptista et al. 1993) and an increase
in striatum (Dziedzicka-Wasylewska et al. 1996) were
reported after the in vivo intragastrical administration of
lithium. In contrast, it has been reported that therapeutic
concentrations of carbamazepine or valproate enhanced basal
releases of dopamine in the prefrontal cortex (Ichikawa and
Meltzer 1999). In addition, carbamazepine and valproate are
metabolized in vivo, which might contribute to the differ-
ences observed in the effects of these drugs in vitro and
in vivo. Moreover, the presence of glia cells expressing b-
adrenergic (Stone et al. 1990; Stone and John 1991) and D2
receptors (Khan et al. 2001) in rat brain cortex increases the
complexity of the regulation of the cAMP levels in vivo
when compared with the in vitro data. Lastly, the other
D2-like receptor subtypes, namely the D3 and D4 receptors,
and the b2- and b3-adrenergic receptors, may also play a role
in the regulation of cAMP levels, and the expression pattern
of these receptors in vitro may be different from that
observed in vivo. Although the in vivo system is rather
complex, providing results that may be affected by multiple
cell–cell interactions, it reflects the effects of the drugs in the
brain, which is also a complex system. Comparison with data
from cell culture experiments is useful, to some extent, for
distinguishing the effect of drugs within the cell from those
resulting from multiple cell–cell interactions.
In this study we provide evidence that the three mood
stabilizers act by different mechanisms on the dopamine
D2-like and b-adrenergic receptor-mediated regulation of
cAMP levels both in vivo and in vitro. Furthermore, we show
that the effects of the mood stabilizers are different in vivo
and in vitro, highlighting the importance of the in vivo
studies. The different effects of the three mood-stabilizing
drugs in the in vivo studies suggest that they have distinct
mechanisms of action. This can be related to differences in
the efficacy of the treatment of manic episodes in clinical
cases, where lithium, but not carbamazepine or valproate, has
been shown to be effective as an acute treatment (Silverstone
and Silverstone 2004). In conclusion, we have shown that
lithium, carbamazepine and valproate affect differentially the
basal and evoked cAMP levels produced by the balance
between b-adrenergic and dopamine D2 receptors, both
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in vitro and in vivo. However, the results did not lead to a
unifying hypothesis for the mechanism of action of these
drugs in bipolar disorder. A common effect on the interaction
between b-adrenergic and dopamine D2 receptors does not
seem to explain the therapeutic efficacy of these drugs,
suggesting that additional signalling systems are involved as
well.
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